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Hypertension and type 2 diabetes are common comorbidities.
Hypertension is twice as frequent in patients with diabetes compared
with those who do not have diabetes. Moreover, patients with
hypertension often exhibit insulin resistance and are at greater risk of
diabetes developing than are normotensive individuals. The major
cause of morbidity and mortality in diabetes is cardiovascular
disease, which is exacerbated by hypertension. Accordingly, diabetes
and hypertension are closely interlinked because of similar risk fac-
tors, such as endothelial dysfunction, vascular inflammation, arterial
remodelling, atherosclerosis, dyslipidemia, and obesity. There is also
substantial overlap in the cardiovascular complications of diabetes
and hypertension related primarily to microvascular and macro-
vascular disease. Common mechanisms, such as upregulation of the
renin-angiotensin-aldosterone system, oxidative stress, inflammation,
and activation of the immune system likely contribute to the close
relationship between diabetes and hypertension. In this article we
discuss diabetes and hypertension as comorbidities and discuss the
pathophysiological features of vascular complications associated
with these conditions. We also highlight some vascular mechanisms
that predispose to both conditions, focusing on advanced glycation
end products, oxidative stress, inflammation, the immune system,
and microRNAs. Finally, we provide some insights into current ther-
apies targeting diabetes and cardiovascular complications and
introduce some new agents that may have vasoprotective therapeutic
potential in diabetes.Received for publication November 11, 2017. Accepted December 7, 2017.
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L’hypertension et le diabète de type 2 sont des affections con-
comitantes frequentes. L’hypertension est deux fois plus frequente
chez les patients atteints de diabète que chez ceux qui n’en sont pas
atteints. De plus, les patients atteints d’hypertension sont souvent
resistants à l’insuline et sont plus susceptibles de souffrir de diabète
que les personnes normotendues. Chez les diabetiques, la principale
cause de morbidite et de mortalite est la maladie cardiovasculaire, qui
est exacerbee par l’hypertension. En consequence, le diabète et l’hy-
pertension sont etroitement interrelies en raison de facteurs de risques
similaires, comme la dysfonction endotheliale, l’inflammation vascu-
laire, le remodelage arteriel, l’atherosclerose, la dyslipidemie et
l’obesite. On observe un chevauchement important entre les compli-
cations cardiovasculaires du diabète et celles de l’hypertension liees
principalement à des maladies microvasculaires et macrovasculaires.
Des mecanismes communs, comme une stimulation du système
renine-angiotensine-aldosterone, un stress oxydatif, une inflammation
et une activation du système immunitaire, sont susceptibles de con-
tribuer à la relation etroite entre le diabète et l’hypertension. Dans cet
article, nous abordons le diabète et l’hypertension comme des affec-
tions concomitantes et nous parlons des caracteristiques physio-
pathologiques des complications vasculaires associees à ces
affections. Nous soulignons egalement certains mecanismes vascu-
laires qui predisposent à ces deux affections, en mettant l’accent sur
les produits finaux de glycation avancee, le stress oxydatif, l’in-
flammation, le système immunitaire et les micro-ARN. Finalement,
nous presentons certaines connaissances sur les traitements actuels
ciblant le diabète et les complications cardiovasculaires et nous
presentons de nouveaux agents qui pourraient avoir un pouvoir vaso-
protecteur chez les patients diabetiques.Type 2 Diabetes Mellitus and Hypertension
The prevalence of obesity and type 2 diabetes (T2D)
continues to rise worldwide as lifestyles associated with low
energy expenditure and high caloric intake are increasinglyadopted, particularly in lower-income and developing coun-
tries. It is predicted that the number of cases of T2D will rise
from 415 million to 642 million by 2040.1 Hypertension is
even more common, rising in prevalence in the same coun-
tries, with a recent worldwide estimate of 1.39 billion cases.2
Although T2D and hypertension can be simply diagnosed
at the bedside, they are each complex and heterogeneous
phenotypes associated with an elevated risk of life-threatening
cardiovascular disease (CVD). Their frequent coexistence in
the same individual is not a coincidence, because aspects of
the pathophysiology are shared by both conditions, particu-
larly those related to obesity and insulin resistance. Fordian Cardiovascular Society. This is an open access article under the CC BY
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T2D had hypertension by the fifth decade of life, whereas
50% of those with hypertension experienced impaired glucose
tolerance or T2D.3
In health, insulin maintains glucose homeostasis by inte-
grated actions on carbohydrate, protein, and lipid metabolism.
Loss of sensitivity to aspects of insulin action (insulin resis-
tance) principally affects the liver, muscle, and adipose tissues
and is selective for glucose and lipid metabolism, eg, sparing
insulin’s action to retain sodium in the distal tubule.4,5
Reduction in insulin-mediated glucose disposal leads to
compensatory hypersecretion of insulin to maintain homeo-
stasis: Glucose intolerance ensues if this endocrine pancreas
response is inadequate, although some obese individuals avoid
T2D by virtue of a supranormal B-cell response.6 Recently,
the role of adipose tissue in these associations has been
increasingly appreciated.7
Diabetes is associated with both macrovascular (involving
large arteries such as conduit vessels) and microvascular
(involving small arteries and capillaries) disease. Chronic
hyperglycemia and insulin resistance play an important role in
the initiation of vascular complications of diabetes and involve
a number of mechanisms including (1) increased formation of
advanced glycation end products (AGEs) and activation of the
receptor for advanced glycation end products (RAGE)
AGE-RAGE axis, (2) oxidative stress, and (3) inflammation.8
In addition, emerging evidence suggests a role for microRNAs
(miRNAs) in the vasculopathy of diabetes (see further on).9
Hypertension is an important risk factor for diabetes-
associated vascular complications, because hypertension itself
is characterized by vascular dysfunction and injury (Fig. 1).
In this review, we focus on vascular complications of dia-
betes and discuss the impact of comorbidities, specifically
hypertension. The role of oxidative stress and inflammation as
“common soil” for metabolic and vascular disease areArterial
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Figure 1. Vascular processes whereby diabetes and hypertension
predispose to cardiovascular disease. Common risk factors promote
diabetes and hypertension, which are associated with atheroscle-
rosis, vascular inflammation, endothelial dysfunction, and structural
remodelling, which lead to macrovascular and microvascular disease.
Vascular damage and endothelial dysfunction is amplified when dia-
betes and hypertension coexist.highlighted. We also discuss how some of the newer agents
used in the treatment of T2D can influence blood pressure
(BP) regulation and the risk of CVD, with an eye to future
developments more specifically targeting vascular protection.Macrovascular Disease
Clinical features
Macrovascular (or cardiovascular) disease of larger conduit
arteries is a complex inflammatory process leading to
myocardial infarction, stroke, and peripheral artery disease.
The primary pathologic process associated with macrovascular
disease is atherosclerosis, which in diabetes is accelerated with
extensive distribution of vascular lesions.10 T2D confers an
approximate 2-fold elevation in CVD risk, equivalent to that
of a previous myocardial infarction.11,12 Moreover, patients
with T2D have poorer outcomes after an acute coronary
syndrome and higher rates of reinfarction and heart failure.13
Elevation of CVD risk begins at the stage of prediabetes in
association with insulin resistance and impaired glucose
tolerance.14 As well as being the diagnostic hallmark of T2D,
hyperglycemia is the principal determinant of microvascular
complications of T2D and plays an important role in the
pathogenesis of CVD. However, in established T2D, it is a
relatively weak modifiable risk factor compared with hyper-
tension, dyslipidemia, and (unfortunately in many pop-
ulations) cigarette smoking.15,16
Pathophysiological features
Insulin resistance is detectable for several years before
the onset of T2D. It is associated with obesity, particularly
central obesity, but may be present in lean individuals with
hypertension.17 During calorie excess, adipocytes in
obese humansdwhether in subcutaneous or visceral
areasdundergo hypertrophy. Visceral adipocytes are more
susceptible to cellular death as they begin to enlarge and
their stromal vascular fraction becomes infiltrated with
macrophages.18
These macrophages around dead adipocytes form “crown-
like structures,” a histologic appearance that is associated with
expression of cytokines (including tumor necrosis factor-a
[TNF-a], interleukin-6 [IL-6]), and inducible nitric oxide
synthase.19 These changes have been shown to coincide with
the onset of insulin resistance and provide a pathophysiolog-
ical link between metabolic and vascular disease.20
In addition to these proinflammatory changes, adipocyte
hypertrophy is associated with larger triglyceride stores, a
higher lipolytic rate, and an atherogenic lipid profile: elevated
concentrations of small dense low-density lipoprotein
cholesterol, high concentrations of triglycerides, triglyceride-
rich remnants, very low-density lipoprotein cholesterol, and
apolipoprotein B, usually in combination with low levels of
high-density lipoprotein cholesterol.7 This profile is associated
with increased production of leptin, decreased production of
adiponectin, higher circulating levels of nonesterified fatty
acids (NEFAs), and activation of mitochondrial oxidative
stress pathways in vascular endothelial cells.7
These proinflammatory and metabolic consequences
of obesity and insulin resistance result in endothelial
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rosis that has been demonstrated not only in hypertension but
also in prediabetes,21 first-degree relatives of individuals with
T2D,22 and even insulin-resistant healthy individuals.22,23 It
is characterized by disruption of the intricate physiological
balance between vasoconstrictors (endothelin, angiotensin II)
and vasodilators (nitric oxide, prostacyclin), growth promot-
ing and inhibitory factors, proatherogenic and antiatherogenic
factors, and procoagulant and anticoagulant factors.24,25 A
substantial body of evidence suggests that impaired
endothelium-dependent vasodilation may in turn contribute
to or exacerbate insulin resistance by limiting the delivery of
substrate (glucose) to key target tissues.26
In addition to these functional changes, an associated
low-grade inflammation in endothelial and smooth muscle
cells of the vascular wall causes cell proliferation, hypertrophy,
remodelling, and apoptosis.27 This accelerates disruption of
the balance between the arterial wall scaffolding proteins
elastin and collagen that determine vascular compliance, a
form of “vascular aging,” which is a characteristic phenotype
in hypertension.28-31 Vascular stiffening leads to widening of
arterial pulse pressure and increased pulsatile shear, exacer-
bating endothelial dysfunction and vascular disease.32Diabetes Hypertension 
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Figure 2. Putative mechanisms whereby diabetes and hypertension
cause vascular disease. Immune cell activation and inflammation are
mediated through oxidative stress. AGEs, advanced glycation end
products; RAAS, renin-angiotensin-aldosterone system; RAGE, recep-
tor AGE.Microvascular Disease
Clinical features
Microvascular disease leads to retinopathy, nephropathy, and
neuropathy, which are major causes of morbidity and mortality
in patients with diabetes. In the United States, diabetic reti-
nopathy affects about 28% of individuals with established
T2D.33 Worldwide it is responsible for 10,000 cases of blind-
ness every year.34,35 Diabetic nephropathy affects about 25% of
individuals with T2D and is the most common cause of renal
failure in the United States.36 Neuropathy affects about 20% of
these individuals, although it is estimated that about 50% have
neuropathy at some point in their lives.36 Each of these organ-
specific microvascular complications has its own unique clin-
ical and histologic features, but all are common with increasing
duration of hyperglycemia and are driven by its downstream
cellular effects, including polyol accumulation (resulting from
saturation of the hexokinase pathway and consequent increased
activity of aldose reductase), AGE-induced injury, increased
vascular permeability, and oxidative stress.8
Follow-up of the Action in Diabetes and Vascular Disease:
Preterax and Diamicron Controlled Evaluation (ADVANCE)
trial cohort has confirmed that the presence of microvascular
complications increases the risk of cardiovascular complica-
tions in individuls with T2D.37 Moreover, the coexistence of
hypertension and retinopathy is a risk factor for the progres-
sion of nephropathy. There is evidence that treatment of
hypertension with angiotensin II receptor blockers can reduce
the progression of retinopathy in addition to well-known
effects on nephropathy.38
Pathophysiological features
Pathognomonic alterations of diabetic microangiopathy
include capillary basement membrane thickening, increased
endothelial permeability, and endothelial and vascular smoothmuscle cell dysfunction. Hyperglycemia is the key stimulus for
these processes by stimulating vasoinjurious signalling path-
ways, activating the polyol pathway, increasing oxidative
stress, stimulating proinflammatory transcription factors, and
activation of immune responses. Similar processes are induced
by hypertension.39Mechanisms of Vascular Complications in
Diabetes and the Impact of Hypertension
A number of interacting mechanisms are in play as sum-
marized in the following sections (Fig. 2).
AGE-RAGE axis
AGEs are compounds that have undergone irreversible
posttranslational modifications because of reactions between
sugars and amino groups on proteins and nucleic acids.
Hyperglycemia accelerates formation of AGEs, which accu-
mulate in the extracellular matrix of vessels and contribute to
vascular damage in diabetes.40 AGEs stimulate production of
reactive oxygen species (ROS), which in turn further enhance
AGE formation. AGEs are also antigenic and hence induce
immune responses.40 In addition to AGEs, dicarbonyl
methylglyoxal, a by-product of glycolysis, accumulates in tis-
sues and contributes to diabetes-associated vascular damage.41
AGEs interact with 2 main types of cell surface receptors:
(1) scavenger receptors, which remove and degrade AGEs, and
(2) receptors for AGEs (RAGE), which trigger specific cellular
signalling responses on AGE binding. RAGE is a member of
the immunoglobulin family and binds many ligands besides
AGEs, such as high mobility group protein B1, S100 calcium-
binding proteins (including calgranulin), amyloid-b-protein,
and amphotericin. AGE-RAGE signals through transforming
growth factor (TGF)-b, NF-kB, mitogen-activated protein
kinases (MAPK; ERK1/2, p38MAPK), and nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases (Nox)
and induces expression of vascular adhesion molecule 1, E-
selectin, vascular endothelial growth factor, and proin-
flammatory cytokines (IL-1b, IL-6, TNF-a).42 In diabetes,
activation of these signalling pathways is increased in vascular
smooth muscle cells, leading to vascular fibrosis, calcification,
inflammation, prothrombotic effects, and vascular damage,
processes underlying diabetic nephropathy, retinopathy,
neuropathy, and atherosclerotic CVD.43 Coexisting hyper-
tension amplifies these complications and contributes to the
578 Canadian Journal of Cardiology
Volume 34 2018accelerated vasculopathy in diabetes.44 Patients with diabetes
have increased tissue and circulating concentrations of AGEs
and soluble RAGE, which is predictive of cardiovascular
events and all-cause mortality. As such, urinary and plasma
AGE levels and soluble RAGE may act as biomarkers for
vascular disease in diabetes.45
Targeting AGE-RAGE has been considered a potential
therapeutic strategy to reduce or prevent CVD in diabetes. A
number of large clinical trials investigating cardiovascular
benefits of alagebrium (ALT-711), which reduces accumula-
tion of AGEs by cleaving AGE cross-links, have been
undertaken. They include Distensibility Improvement and
Remodeling in Diastolic Heart Failure (DIAMOND;
NCT00043836), Systolic and Pulse Pressure Hemodynamic
Improvement By Restoring Elasticity (SAPPHIRE;
NCT00045981), Systolic Hypertension Interaction With Left
Ventricular Remodeling (SILVER; NCT00045994), Systolic
Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA;
NCT00089713), Beginning a Randomized Evaluation of the
AGE Breaker Alagebrium in Diastolic Heart Failure I
(BREAK-DHF-I; NCT00662116), and Evaluating the Effi-
cacy and Safety of Alagebrium (ALT-711) in Patients With
Chronic Heart Failure (BENEFICIAL; NCT00516646).
However few data have been published from these studies.
Some small clinical studies demonstrated cardiovascular benefit
in patients with diabetes and hypertension.46 In particular,
alagebrium improved endothelial function, reduced aortic
stiffness, and increased vascular compliance.47
Oxidative stress and Nox
Oxidative stress is a key mechanism of glucotoxicity in
diabetes, as evidenced by increased vascular ROS generation
in response to hyperglycemia and accumulation of oxidation
by-products of lipids, proteins, and nucleic acids.27 NADPH
oxidases and dysfunctional endothelial nitric oxide synthase
are principal sources of increased ROS in human vasculature
in T2D.48,49 ROS interact with DNA and stimulate many
redox-sensitive signalling pathways that lead to inflammation,
fibrosis, and vascular damage. Increased vascular oxidative
stress in diabetes and hypertension promotes posttranslational
oxidative modification of proteins, causing cellular damage
and vascular dysfunction. Hyperglycemia also induces acti-
vation of redox-sensitive protein kinase C and polyol and
hexosamine pathways, further contributing to mitochondrial
dysfunction, oxidative stress, endoplasmic reticulum stress,
and consequent cellular damage.50 Oxidative stress is also
associated with reduced bioavailability of the vasodilator nitric
oxide, causing endothelial dysfunction.
Diabetes-induced oxidative stress is caused by numerous
processes, including glucose-stimulated mitochondrial respi-
ration, endoplasmic reticulum stress, activation of the renin-
angiotensin system (which is pro-oxidant), decreased
vascular antioxidant capacity, reduced activity of the master
antioxidant transcription factor nuclear factor-erythroid 2-
related factor (Nrf-2), and activation of Nox isoforms.51 Of
these mechanisms activation of Nox types is particularly
important. Four Nox isoforms have been demonstrated in
human vessels, including Nox1, Nox2, Nox4, and Nox5.
Nox-derived ROS influence redox-sensitive signalling path-
ways in vascular cells such as MAPKs, protein tyrosinephosphatases, transcription factors, Ca2þ channels, ion
transporters, and proinflammatory genes.52 In diabetes and
hypertension, oxidative stress (increased ROS bioavailability)
promotes vascular inflammation, fibrosis, and injury, pro-
cesses that are normalized by Nox inhibitors or ROS scav-
engers, or both. Nox1, but not Nox4, seems to be important
in atherosclerosis in diabetes, as we demonstrated in Nox1-
deficient mice on the atherosclerosis-prone ApoE/ back-
ground made diabetic with streptozotocin.53 Nox4 has been
implicated in renal injury in mouse models of diabetes, effects
that are ameliorated with Nox1/4 inhibitors and in mice
deficient in Nox4.54,55 Nox5 may also be important in
diabetes-associated vascular injury and nephropathy. We
demonstrated that renal Nox5 expression is increased in pa-
tients with diabetic nephropathy. Moreover, in transgenic
mice with podocyte-specific expression of human Nox5, renal
injury was amplified by diabetes.56 Similar findings were
observed in mice expressing human Nox5 in a vascular
smooth muscle cell-specific manner.57 Although extensive
experimental evidence showed a renoprotective effect of Nox4
inhibition in diabetes, a recent clinical study using
GKT137831, a Nox1/4 inhibitor, failed to show improve-
ment in renal function in patients with diabetic nephropa-
thy.58 Whether targeting Nox5 may have better clinical
outcomes is unclear, because to date there are no Nox5 in-
hibitors available.
Inflammation and the immune system
Links between inflammation and the immune system with
metabolic dysfunction, hypertension, and cardiovascular
morbidity are supported by extensive experimental data.59
This encompasses a number of immune metabolic aspects,
including the key role of the tricarboxylic cycle or sphingo-
sine-1-phosphate in the regulation of vascular inflamma-
tion.59,60 Clinical studies have shown that patients with T2D
have increased total leukocyte counts, particularly neutrophils
and lymphocytes, that correlate with insulin sensitivity,61
which is in part mediated by inflammatory changes of adi-
pose tissue.62 Inflammatory biomarkers are also useful in
developing targeted cardiovascular therapies in the context of
metabolic dysfunction.63 The link between inflammation and
T2D is further supported by genetic studies and clinical trials
showing protective effects of immune-targeted therapies and
anti-inflammatory actions of classic antidiabetes drugs.64
Circulating and locally produced effector cytokines such as
TNF-a, interferon-g, IL-1b, and IL-12 may influence insulin
sensitivity of peripheral tissues and can modulate insulin
release in the pancreatic islets.65-68 Increased glucotoxicity and
lipotoxicity have been associated with immune cell infiltration
of target tissues, thereby affecting diabetes-associated target
organ damage and cardiovascular complications,68,69
including the development of metabolic cardiomyopa-
thy.70,71 Inflammation is a key modulator of metabolic and
diabetic CVD.
Genetic evidence. Although genome-wide association
studies (GWAS) for insulin resistance or T2D have not shown
strong associations with immune-related genes, numerous
metabolic traits are linked to immune-related loci.72 Studies
integrating metabochip approaches with GWAS have shown
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pathways (such as MAP3K1), nuclear factor kappa B (NF-kB)
regulators (MACROD1), inflammasome activators (NRF3),
and interferon-g receptor genes associate with T2D.73,74 This
also corresponds to results of recent large T2D GWAS that
identified genes related to macrophage function and antigen
presentation (MAEA, ST6GAL1), and T-cell signalling (CMIP
or PTPRJ).72,75 While trying to interpret these important
studies, it should be appreciated that GWAS approaches have
limitations, because only a small component of heritability of
complex traits is directly explainable by single-gene
variability.76
Clinical evidence. Increasing clinical evidence indicates an
immune component in T2D and its cardiovascular compli-
cations. Immune-targeted therapies currently available for the
treatment of rheumatoid arthritis and autoimmune disorders,
including anti-TNF therapies, may prevent insulin resistance
as well as cardiovascular risk.64,77 A recent meta-analysis of
studies with anti-TNF agents supports an overall protective
effect of anti-TNF therapies on lifetime risk of diabetes as well
as insulin sensitivity and obesity.74
A recent large proof of concept trial of anti-inflammatory
therapy in patients after myocardial infarction (A Random-
ized, Double-blind, Placebo-controlled, Event-driven Trial of
Quarterly Subcutaneous Canakinumab in the Prevention of
Recurrent Cardiovascular Events Among Stable Post-
Myocardial Infarction Patients With Elevated hsCRP
[CANTOS]; canakinumab targeting IL-1b) showed a clear
reduction in the rate of cardiovascular events, albeit with an
associated increase in the rate of severe infections.78 These
results were particularly evident in high-risk patients, although
effects on metabolic profile remain unclear.78 However, evi-
dence that IL-1b targeting may have significant metabolic
benefits has been well established, as evidenced by improved
profile insulin sensitivity in response to IL1-b blockade.79 The
potential beneficial effects of anti-inflammatory and immune-
modulating agents in T2D and its complications may relate to
direct vasoprotective effects. These studies have led to the
rapid development of the concept of immunometabolism,
clearly linking metabolic changes in the tissues to the regu-
lation of inflammation as well as metabolic status of immune
cells to their activation.28,56 The latter can be characterized by
a switch between oxidative phosphorylation and anaerobic
glycolysis, which is observed in macrophages and T cells.30,59
This also emphasizes the importance of the interplay between
vascular oxidative stress and the development of inflammation
in adipose tissue and the vasculature.
Anti-inflammatory properties of antidiabetic therapies.
Classic approaches improving metabolic health, such as
weight reduction and the use of metformin, statin drugs,
pioglitazone, and insulin have been shown to have anti-
inflammatory effects. Metformin reduces C-reactive protein
levels by 13%. More recently, a novel anti-inflammatory
mechanism of metformin affecting M1/M2 polarization of
macrophages has been shown to reduce obesity-associated
low-grade inflammation, possibly because of adenosine
monophosphate-activated protein kinase (AMPK) activation.
These effects were modulated by AMPK and the AMPKanalogue 5-aminoimidazole-4-carboxamide ribonucleotide,
effects that appear stronger than those of metformin.80 Recent
studies have shown that salicylates have anti-inflammatory
effects that involve inhibition of NF-kB and that they also
prevent diabetes and improve insulin resistance in experi-
mental models and humans.81,82 Drugs such as glicazide and
troglitazone, as well as N-acetylcysteine, decrease inflamma-
tory markers in patients with diabetic nephropathy and
diabetic retinopathy.83
Epigenetics is another mechanism that may influence
inflammation and immunometabolism in diabetes.59 Histone
deacetylase (HDAC) inhibitors cause NF-kB inhibition
through acetylation of the p65 subunit. Givinostat (formerly
ITF2357), an orally active HDAC inhibitor, has been shown
to prevent the development of diabetes.84,85 Similarly, acti-
vation of sirtuin1, which is involved in inflammation, meta-
bolism, and aging, has been shown to have anti-inflammatory
properties in diabetes.86MiRNAs, Diabetes, and Vascular Complications
miRNAs are a group of noncoding RNAs that are multi-
functional. They fine tune gene expression and have been
implicated in various pathologic processes, including T2D
and the development of diabetic vascular complications. A
number of pancreatic B-cellespecific miRNAs have been
identified, including miR-375, miR-124a, miR-96, miR-7a,
miR7a2, miR-30d, miR-9, miR-200, miR-184, and let-7.87
These play a role in pancreatic function, insulin secretion,
and glucose tolerance. Differential miRNA signatures have
been identified among prediabetic individuals, patients with
diabetes, and patients with diabetes and vascular complica-
tions, suggesting that miRNAs may be novel biomarkers.
Diabetic cardiovascular complications are associated with
increased levels of miR-223, miR-320, miR-501, miR504,
and miR1 and decreased levels of miR-16, miR-133,
miR-492, and miR-373.9 Whether these changes in miRNA
are simply biomarkers of disease or whether they are directly
involved in the vasculopathy of diabetes remains unclear.
Treatment of diabetes mellitus and its cardiovascular
complications
Once T2D has been diagnosed, the aim of achieving
glucose control is principally to avoid microvascular compli-
cations. There are some benefits with respect to macrovascular
complications, but this is dependent on the profile of indi-
vidual drug classes and even appears to be different for agents
within the same class.88 The role of BP lowering to improve
prognosis in T2D has been established since the UK Pro-
spective Diabetes Study (UKPDS) in 1998.89,90 However,
more recently, more widespread use of glucose-lowering
agents that reduce (rather than increase) weight, lower BP,
and have beneficial “off-target” effects (as demonstrated in
recent large cardiovascular outcome trials) facilitates cardio-
vascular risk factor control and is playing a role in improving
the cardiovascular prognosis of T2D.91,92
Achieving glucose control in T2D begins with weight
management. Particularly in the first 8 years after diagnosis,
normal glucose tolerance can be restored if radical weight
reduction can be achieved, most effectively using a very low
580 Canadian Journal of Cardiology
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also occur after successful bariatric surgery, particularly the
Roux-en-Y procedure.94 The mechanism may involve reduc-
tion in ectopic fat, and consequent relief from its proin-
flammatory effects, in and around the pancreatic islets of
Langerhans.95
All current glucose-lowering guidelines suggest the early
addition of metformin as first-line therapy. Unlike the sul-
phonylureas, which augment insulin secretion, metformin
lowers blood glucose levels principally by decreasing hepatic
glucose production and promoting weight reduction (with
little effect on BP). Among the many proposed mechanisms of
action of metformin is activation of AMPK: This is now
thought to be a secondary effect of inhibition of the mito-
chondrial respiratory chain.96 Such effects of metformin may
act directly (ie, independent of blood glucose lowering) on
other tissues, including vascular endothelial cells. Metformin
treatment is associated with improvements in endothelial
biomarkers and reduction in plasma high-sensitivity C-reac-
tive protein levels.97,98 It was associated with cardiovascular
benefit in the landmark UKPDS.99
Other second-line agents used in glucose lowering include
pioglitazone, a thiazolidinedione that directly promotes the
differentiation of adipocytes within subcutaneous adipose
depots (by activation of peroxisome proliferator-activated
receptor-g), thus promoting storage of non-esterified fatty
acids (NEFAs).100 Pioglitazone reverses many of the metabolic
features associated with insulin resistance without much effect
on BP. Anti-inflammatory effects have been demonstrated in
human adipose tissue biopsy samples and also in some animal
models.101 There was great hope in the 1990s that agents
from this class would have major benefits for the cardiovas-
cular system, a hypothesis that was to some extent supported
by the results of the Prospective Pioglitazone Clinical Trial in
Macrovascular Events (PROACTIVE) cardiovascular
outcome trial, although beneficial effects were offset by weight
gain and fluid retention.102
More recently introduced classes of glucose-lowering
agents have heralded an exciting era in T2D pharmaco-
therapy because they are associated with weight reduction, BP
reduction, and, importantly, reduced rates of major adverse
events in long-term cardiovascular outcome trials.91,92,103
Glucagon-like peptide-1 agonists are injectable agents that
augment glucose-dependent insulin secretion (the “incretin”
effect), delay gastric emptying (enhancing satiety), and have
central effects on hypothalamic nuclei to reduce appetite.104
Systolic BP is lowered beyond the effect that would be
expected purely from weight loss, and there is an improve-
ment in pulse-wave velocity, reflecting a reduction in arterial
stiffness. However, the time course of cardiovascular event
reduction in the Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results (LEADER)
trial suggests a primary antiatherosclerotic rather than hemo-
dynamic effect.91 Indeed, liraglutide has been shown to have
anti-inflammatory actions on the cardiovascular system in a
number of preclinical and clinical studies.103,105
SGLT2 inhibitors promote lowering of the threshold for
urinary glucose excretion: an additional glucose equivalent to
300 kcal per day is therefore cleared by the kidneys, pro-
moting weight loss and a catabolic state with increased
circulating ketone bodies and NEFAs.106 There areassociated reductions in BP and plasma volume, which
together may have been responsible for the early reduction in
cardiovascular event rates seen with empagliflozin in Empa-
gliflozin, Cardiovascular Outcomes, and Mortality in Type 2
Diabetes (EMPA-REG OUTCOME) trial.91 A shift in fuel
substrate metabolism from glucose to NEFAs and ketones,
including by the myocardium, is 1 of the mechanisms by
which SGLT2 inhibitors may provide cardiovascular pro-
tection,107 but studies in apoE knockout mice and Zucker
diabetic fatty rats suggest that anti-inflammatory effects may
also play a role.108
Diabetes, vasoprotection, and potential new therapies
Data from landmark clinical trials in T2D including
UKPDS, ADVANCE, and Action to Control Cardiovascular
Risk in Diabetes (ACCORD) demonstrate that treating
comorbidities including hypertension and hypercholesterole-
mia is a more effective strategy for reducing cardiovascular
complications than targeting blood glucose levels with con-
ventional agents.109 Antihypertensive drugs such as
angiotensin-converting enzyme inhibitors, angiotensin-
receptor blockers, mineralocorticoid-receptor blockers, and
calcium-channel blockers may have direct vasoprotective
effects, and their use may contribute, at least in part, to
reduced vascular complications in patients with diabetes and
concomitant hypertension.110 Tight control of BP has been
shown to reduce cardiovascular risk in T2D: most recent US
and Canadian guidelines recommend a target of < 130/80
mm Hg.111,112 Statin drugs and clopidrogel are also vaso-
protective and may have extra benefit in patients with
diabetes. Some of the beneficial effects of these drugs have
been attributed to their antioxidant and anti-inflammatory
properties.
New therapeutic approaches targeting oxidative stress,
inflammation, and fibrosis are currently being developed to
treat diabetes-associated cardiovascular complications.113 In
particular, drugs that increase Nrf-2 activity, such as bardox-
olone methyl, and strategies to inhibit the pyrin domain
containing 3 (NLRP3) inflammasome, may have therapeutic
potential. A novel bardoxolone methyl derivative, dh404, has
been shown to attenuate endothelial dysfunction, reduce
Nox1 expression, decrease oxidative stress, and inhibit
inflammation in diabetic mice, suggesting that upregulation of
Nrf2 may have therapeutic potential to limit diabetes-
associated vascular damage.114 Another example includes
inhibition of dipeptidyl peptidase-4 by linagliptin, which
reduces obesity-related insulin resistance and inflammation by
regulating M1/M2 macrophage status.115 Other therapies on
the horizon for the treatment of cardiovascular complications
of diabetes include pentoxifylline (methylxanthine derivative
and nonspecific phosphodiesterase inhibitor with anti-
inflammatory and antifibrotic effects), ruboxistaurin (selec-
tive protein kinase C-b inhibitor), pirfenidone (TGF-b
inhibitor), bindarit (MCP-1/CCL2 inhibitor), sulodexide (an
oral formulation composed of 2 glycosaminoglycans),
AKB-9778 (Tie2 activator), baricitinib (JAK/STAT inhibi-
tor), and Nox inhibitors.116 The clinical benefit of these
compounds awaits further confirmation, and novel nano-
therapeutic approaches are being developed to target
inflammation.117
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Diabetes, Hypertension, and Vascular ComplicationsConclusions
Diabetes is associated with an increased risk of CVD,
which is exaggerated with coexistent hypertension. Many of
the underlying molecular mechanisms, including oxidative
stress, inflammation, and fibrosis causing microvascular and
macrovascular complications of diabetes, also cause vascular
remodelling and dysfunction in hypertension. Controlling
comorbidities, especially hypertension, and targeting strategies
to promote vascular health, may be especially important in
reducing the microvascular and macrovascular complications
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